

LEADERS IN ONCOLOGIC INTERVENTIONS

# ECIO 2019

10<sup>th</sup>  
EDITION

European Conference  
on Interventional Oncology

April 8-11  
Amsterdam, Netherlands

[www.ecio.org](http://www.ecio.org)

PRELIMINARY  
PROGRAMME

CIRSE

Cardiovascular and Interventional Radiological Society of Europe

# LEADERS IN ONCOLOGIC

## Join us for the 10<sup>th</sup> European Conference on Interventional Oncology!

Back in 2008, the very first ECIO meeting was held in Florence. Interventional oncology was only just emerging as a recognised discipline – a small but significant number of IRs had started to integrate interventional oncology into their clinical practice and get involved in their local tumour boards, and the ECIO meeting was introduced to further support this exciting trend.

Fast forward a few years, and the landscape has changed drastically. From that first meeting, the conference has grown – even becoming an annual event instead of a biennial one – and most recently, almost 1,400 attendees joined us in Vienna from around the globe. Most tellingly, not all of these were interventional radiologists: many of those attending, and who serve on the faculty, hail from disciplines such as hepatology, medical oncology, radiotherapy and surgical oncology. This collaborative and patient-focused approach allows those attending to get a clear and comprehensive overview of the current best practice in loco-regional tumour and combined therapies.

## Multidisciplinary, multi-organ

The 2019 programme builds on this positive trend, with a diverse expert faculty ready to lead discussions on a wide number of oncological applications. Alongside key areas of interest, such as HCC, lung cancers and colorectal metastases, the programme will cover more novel applications, including cholangiocarcinoma, thyroid and adrenal cancers, and for the first time ever, localised prostate cancer. Constructive debate is once more on the cards, and we are particularly excited about the *Controversies in Kidney Cancer* session, where a multidisciplinary panel will address issues such as robotic partial nephrectomy, the malignant potential of biopsy and the best ablation modalities.

The programme will also branch out to address emergency situations that the interventional oncologist may face, such as abdominal and pelvic bleeding, haemoptysis, superior vena cava syndrome and how to manage ruptured HCC.



A. Gangi

A. Denys

D.J. Breen

L. Crocetti

T. de Baère

F. Fanelli

T.K. Helmberger

R. Lencioni

## Committees

### Scientific Programme Committee

**Afshin Gangi (FR), Chairperson**

**Alban Denys (CH), Deputy Chairperson**

David J. Breen (UK)

Laura Crocetti (IT)

Thierry de Baère (FR)

Fabrizio Fanelli (IT)

Thomas K. Helmberger (DE)

Riccardo Lencioni (IT)

Gabriel Malouf (FR)

Robert A. Morgan (UK)

Jean Palussière (FR)

Philippe L. Pereira (DE)

Warner Prevoo (NL)

Tarun Sabharwal (UK)

José Urbano (ES)

Otto M. van Delden (NL)

### Local Host Committee

**Otto M. van Delden (Amsterdam), Chairperson**

Marc C. Burgmans (Leiden)

Rutger C.G. Bruijnen (Arnhem)

Jurgen Fütterer (Nijmegen)

Martijn R. Meijerink (Amsterdam)

Adriaan Moelker (Rotterdam)

Warner Prevoo (Amsterdam)

Christiaan van der Leij (Maastricht)

Mirjam Koopman (Utrecht)

Marc G.H. Besselink (Amsterdam)

Cees Verhoef (Rotterdam)

Hein-Josef Klümpen (Amsterdam)

# INTERVENTIONS

## Fresh learning formats

As ever, a wide range of session types will be offered – the traditional lecture setting will be complemented by our popular Video Learning session, Multidisciplinary Tumour Board and Hands-on Device Training sessions, six of which will be offered, showcasing cutting-edge RFA, microwave, cryo and image-guidance technologies.

New additions in 2018, such as the Free Paper sessions and Poster Area (which featured chosen researchers from the first-ever abstract submission at ECIO), and the Safe Sedation and Anaesthesia Training workshops, will be continued in 2019. The newly introduced Basic Course in MSK interventions was also very well received and for the 10<sup>th</sup> conference, its focus will be on liver interventions. This will be carried out in small groups over three two-hour sessions, covering a range of therapies and techniques.

As always, visitors will also have access to the world's largest interventional oncology device exposition!

## The city of straight-talking

For our first milestone meeting, we head to laid-back Amsterdam, a city known for its open yet no-nonsense attitude. Paired with the excellent facilities offered by the RAI Amsterdam congress centre, the stage is set for productive discussions about best practice and current trends in interventional oncology.

Together with our partner Kuoni DMC we have reserved the best located and most suitable conference hotels and we encourage all delegates to book accommodation via the official ECIO hotel booking platform.

Join us in beautiful Amsterdam this springtime to share ideas and enhance your technical expertise – we look forward to seeing you there!



G. Malouf

R.A. Morgan

J. Palussière

P.L. Pereira

W. Prevoo

T. Sabharwal

J. Urbano

O.M. van Delden

## Content

- 2** Preliminary Faculty
- 3** Honorary Lecture
- 4** Collaborating Against Cancer Initiative
- 5** 10 reasons to attend
- 6-7** Programme Overview
- 8-18** Scientific Programme
- 19** Hands-on Device Training / Safe Sedation
- 20** Basic Course
- 21** Registration / CME / Important Addresses
- 22-23** Accommodation / City Map



## Preliminary Faculty

*Subject to change*

Abadal J. (Madrid/ES)	Garcia Marcos R. (Valencia/ES)	Narayanan G. (Miami, FL/US)
Ahmed M. (Boston, MA/US)	Garcia-Monaco R.D. (Buenos Aires/AR)	Orsi F. (Milan/IT)
Antonuzzo A. (Pisa/IT)	Garnon J. (Strasbourg/FR)	Ottensmeier C. (Southampton/UK)
Arai Y. (Tokyo/JP)	Gaubert J.Y. (Marseille/FR)	Palussière J. (Bordeaux/FR)
Arnold D. (Hamburg/DE)	Gervais D.A. (Boston, MA/US)	Papagelopoulos P.J. (Athens/GR)
Atwell T.D. (Rochester, MN/US)	Gillams A. (London/UK)	Patel N. (London/UK)
Bargellini I. (Pisa/IT)	Goldberg S.N. (Jerusalem/IL)	Pereira P.L. (Heilbronn/DE)
Bell J.K. (Manchester/UK)	Golzarian J. (Minneapolis, MN/US)	Popert R. (London/UK)
Bex A. (Amsterdam/NL)	Gomez F.M. (Barcelona/ES)	Prevo W. (Amsterdam/NL)
Borensztein M. (Buenos Aires/AR)	Guiu B. (Montpellier/FR)	Pua U. (Singapore/SG)
Breen D.J. (Southampton/UK)	Hakimé A. (Villejuif/FR)	Rao P. (Strasbourg/FR)
Brown N.I. (Brisbane/AU)	Hawkins M. (Oxford/UK)	Ricke J. (Munich/DE)
Burrel M. (Barcelona/ES)	Heijmink S.W.T.P. (Amsterdam/NL)	Ronot M. (Villejuif/FR)
Buy X. (Bordeaux/FR)	Helmberger T.K. (Munich/DE)	Ryan A.G. (Waterford City/IE)
Callstrom M.R. (Rochester, MN/US)	Hocquet A. (Lausanne/CH)	Salem R. (Chicago, IL/US)
Cazzato R.L. (Strasbourg/FR)	Hoffmann R.-T. (Dresden/DE)	Schmit G. (Rochester, MN/US)
Cervelli R. (Pisa/IT)	Ilyas S. (London/UK)	Schmit G.D. (Rochester, MN/US)
Champiat S. (Villejuif/FR)	Irani F.G. (Singapore/SG)	Sharma R. (London/UK)
Cioni R. (Pisa/IT)	Jennings J.W. (St. Louis, MO/US)	Smit E.F. (Amsterdam/NL)
Corcoran R.B. (Boston, MA/US)	Jougou J. (Bordeaux/FR)	Sofocleous C.T. (New York, NY/US)
Crocetti L. (Pisa/IT)	Kelekis A.D. (Athens/GR)	Solbiati L. (Rozzano/IT)
de Baère T. (Villejuif/FR)	Kenny L.M. (Brisbane/AU)	Solomon S.B. (New York, NY/US)
Denys A. (Lausanne/CH)	Klumpen H. (Amsterdam/NL)	Suh R.D. (Los Angeles, CA/US)
Deschamps F. (Villejuif/FR)	Kurtz J.-E. (Strasbourg/FR)	Tselikas L. (Villejuif/FR)
Digkila A. (Lausanne/CH)	Kurup A.N. (Rochester, MN/US)	Tsoumakidou G. (Lausanne/CH)
Dromain C. (Lausanne/CH)	Lam M.G.E.H. (Utrecht/NL)	Urbano J. (Madrid/ES)
Ducreux M. (Villejuif/FR)	Lencioni R. (Pisa/IT)	van Delden O.M. (Amsterdam/NL)
Duran R. (Lausanne/CH)	Mahnken A. (Marburg/DE)	van der Leij C. (Maastricht/NL)
Feydy A. (Paris/FR)	Malouf G. (Strasbourg/FR)	van Gulik T.M. (Amsterdam/NL)
Filippiadis D. (Athens/GR)	Marcia S. (Cagliari/IT)	van Strijen M.J.L. (Nieuwegein/NL)
Fleming S. (Dundee/UK)	Martens U. (Heilbronn/DE)	Varela M. (Oviedo/ES)
Fridmann W.H. (Paris/FR)	Masala S. (Rome/IT)	Veltri A. (Orbassano/IT)
Fuchs M. (Munich/DE)	Masi G. (Pisa/IT)	Vogel A. (Hannover/DE)
Fütterer J. (Nijmegen/NL)	Meijerink M.R. (Amsterdam/NL)	Wood B.J. (Bethesda, MD/US)
Gangi A. (Strasbourg/FR)	Napoli A. (Rome/IT)	



## Honorary Lecture

### Ricardo D. García-Mónaco

Ricardo García-Mónaco completed his medical degree with honours at the University of Buenos Aires in 1981, before successfully sitting the boards of Radiology and Imaging Diagnosis of Argentina's National Ministry of Health in 1988. A fluent speaker of Spanish, English and French, he acquired a Diplome de Résonance Magnétique from the University of Paris in 1990, before returning to Argentina and taking up a double post as Associate Professor of Radiology and Programme Director of Interventional and Vascular Radiology at the University of Buenos Aires in 1996.

Prof. García-Mónaco completed his Doctorate (PhD) in medicine in 2004, and became a full Professor of Radiology at the University of Buenos Aires in 2007, the same year he became Director of the university's radiology medical school programme, a position he still holds.

His extensive post-graduate training took him to many corners of the earth: following his initial residencies at the Hospital Italiano in Buenos Aires, he completed training in Angiography and Interventional Radiology at Bicêtre Hospital, University of Paris from 1988-1992, and Visiting Fellowships at both New York University, USA and Toronto Western Hospital, Canada in 1990.

Returning then to France, he worked as Médecin Assistant a Titre Etranger at Hôpital Bicêtre and as a Consultant IR at the renowned Institut Gustav Roussy in Villejuif. Since 1992, Prof. García-Mónaco has been Head of Endovascular Therapy and Interventional Radiology at Hospital Italiano, and since 2005, also holds the post of Chairman of the hospital's Department of Radiology.

His international medical career is complemented by his active membership of many medical associations, including the Radiological Society of Argentina (SAR), the World

Federation of Therapeutic and Interventional Neuroradiology, CIRSE, RSNA, the Société Française de Radiologie (SFR), ESR, the International Society for the Study of Vascular Anomalies (ISSVA), the Society of Hepato-Gastroenterology and the International Society for Strategic Studies in Radiology (ISSSR). He is an SIR Fellow, and is also a Founding Member of the Argentine College of Vascular and Interventional Radiology (CARVI), which he currently serves as President. Prof. García-Mónaco is also the current president of the International Society of Radiology, and has previously served as President of Sociedad Argentina de Radiología and the Interamerican College of Radiology.

Prof. García-Mónaco is a prolific researcher and educator, having delivered 477 scientific or educational presentations at national or international congresses, and having 227 scientific papers published in national or international journals. He is also author or co-author over 70 books or book chapters. He is a peer-reviewer for acclaimed journals such as *CVIR*, *Radiology*, *JVIR*, *Thrombosis* and *Radiographics*, and serves on the Editorial Committees of *Interventional Oncology 360*, *Digestive Disease Interventions* and *Revista de la Sociedad Iberoamericana de Intervencionismo*, amongst others.

Prof. García-Mónaco has received awards for 39 scientific presentations (24 national and 15 international), and has been conferred honorary membership of ESR, RSNA, the Société Française de Radiologie and the Societa Italiana de Radiologia Medica (SIRM), amongst others. He has received the Gold Medal of the Argentine Society of Radiology (SAR), and has served on many advisory boards and educational committees, including his current posts as a Member of the ISSSR Membership Committee, Member of RSNA Vascular/Interventional Education Exhibits Subcommittee and Chairman of the IT Education Committee of ISR.

### Honorary Lecture Interventional Oncology: from Europe to South America

Tuesday, April 9  
10:30-11:30



# ECIO 2019

**Collaborating Against Cancer Initiative**

## €100,000 Education Grant

**CIRSE supports the "Collaborating Against Cancer" initiative with €100,000!**

**The ECIO initiative allows radiologists with a full registration for ECIO 2019 in Amsterdam to invite their non-radiologist colleague to the conference free of charge.**

**The first 100 referring physicians to sign up will receive free registration and up to €1,000 travel support.**

**For further information and registration please go to [www.ecio.org](http://www.ecio.org)**

# 10 years of ECIO – 10 reasons to attend

## 1 Hands-on Device Training

These practical learning sessions let you get to grips with currently available technologies. Choose from one of the workshops on RFA, microwave or cryo technologies, or learn more about state-of-the-art image guidance!

## 2 Video Learning Session

This interactive session format has become a firm favourite in the ECIO programme. This year, experts will talk you through specific lung, bone and kidney interventions, as well as three liver cases: ablation, TACE and extended resection of Klatskin tumour.

## 3 Morbidity and Mortality Conference

Top-quality care requires sober reflection on cases that didn't go to plan. Join leading experts as they discuss what went wrong and how we can learn from it: an essential part of every oncologist's learning curve.

## 4 Expert Faculty

The lively cross-specialty discussions that ECIO has become renowned for will continue this year, with field-leading experts joining us a Multidisciplinary Tumour Board on MSK, Clinical Focus Sessions on immunotherapy and SBRT, and more! And why not sign your own colleagues up for the Collaborating Against Cancer Initiative?

## 5 Dynamic Programme

The comprehensive scientific programme will examine many novel IO applications, including intrahepatic cholangiocarcinoma; thyroid, pancreas, adrenal, lymph and breast cancers; and, new this year, localised prostate cancer!

## 6 Basic Courses

Introduced last year to great acclaim, the Basic Courses cater for beginners in the field of IO. This year's programme will focus on liver interventions, with courses addressing the fundamentals, TACE, liver ablation and radioembolisation.

## 7 Emergency in Oncology

This unique Clinical Focus Session will examine the emergency situations that can confront a practitioner of IO. From head and neck to abdominal and pelvic bleeding, our experts will also address haemoptysis, superior vena cava syndrome and how to manage ruptured HCC.

## 8 Debate: Controversies in Kidney Cancer

A multi-specialty meeting offers a golden opportunity to debate current medical controversies. See experts weigh in on kidney cancer issues such as the malignant potential of biopsy, robotic partial nephrectomy and the best ablation modalities.

## 9 Unique Technical Exhibition

ECIO's technical exhibition is the world's largest device exposition that is purely focused on cancer diagnosis and treatment, and offers delegates a unique opportunity for interaction with device manufacturers.

## 10 Amsterdam

The laid-back atmosphere and leafy canals of Amsterdam provide a perfect backdrop for practical problem solving, pragmatic decision making and frank discussion. Join us this springtime to continue the conversation on how to advance interventional oncology!

## Monday, April 8

## Tuesday, April 9

08:00	Satellite Symposia			Satellite Symposia		
09:00	<b>CF 101</b> HCC – what you should know p8			<b>CF 801</b> Intrahepatic cholangiocarcinoma p12		<b>CF 802</b> Immunotherapy: actual clinical applications – what an IR should know p12
10:00	Break			Break		
11:00	<b>CF 201</b> Cancer immunology: basics p8	<b>TF 202</b> Image guidance: case-based discussion p8	<b>TA-HDT 1</b> Tumour ablation – RFA p9	<b>HL 901</b> Honorary Lecture p12	<b>TA-HDT 3</b> Tumour ablation – Microwave p12	
12:00	Lunch break			Lunch break		
13:00	Satellite Symposium			Satellite Symposium		
14:00	Satellite Symposium			Satellite Symposium		
15:00	Break			Break		
16:00	<b>CF 401</b> Hepatocarcinoma – practice in 2019 p9	<b>CF 402</b> Other organ p9	<b>TA-HDT 2</b> Tumour ablation – RFA p10	<b>CF 1101</b> Lung metastases p13	<b>CF 1102</b> Colorectal liver metastases p13	<b>TA-HDT 4</b> Tumour ablation – Microwave p13
17:00	Break			Break		
18:00	<b>CF 501</b> Colorectal p10	<b>TF 502</b> Tips and tricks: case-based discussion p10	<b>BC 503</b> Basic Course: Liver p11	<b>CF 1201</b> SBRT of liver and lung tumors: understanding mechanisms and limitations p14	<b>CF 1202</b> MSK: curative treatment p14	<b>BC 1203</b> Basic Course: Liver p14
19:00	Satellite Symposia			Satellite Symposia		



e-voting



Sessions include lectures that are recommended for EBIR preparation



## Wednesday, April 10

## Thursday, April 11

30						
45	Satellite Symposia					
08:00						
15						
30						
45						
09:00	<b>CF 1501</b> Kidney cancer – current controversies <i>p15</i>	<b>CF 1502</b> Immunotherapy: where are we heading (research) <i>p15</i>		<b>CF 2101</b> New indications: localised prostate cancer <i>p18</i>	<b>CF 2102</b> Quality issues, research and patterns of practice in Interventional Oncology <i>p18</i>	
15						
30						
45						
10:00	Break			Break		
15						
30						
45	<b>CF 1601</b> Cancer pain management <i>p15</i>	<b>CF 1602</b> Emergency in oncology <i>p16</i>	<b>TA-HDT 5</b> Tumour Ablation – Cryo- and laser <i>p16</i>	<b>MM 2201</b> Morbidity & Mortality Conference <i>p18</i>		
11:00						
15						
30						
45						
12:00	Lunch break					
15						
30	Satellite Symposium					
45						
13:00	Satellite Symposium					
15						
30	Satellite Symposium					
45						
14:00	Satellite Symposium					
15						
30	Break					
45						
15:00	<b>MTB 1801</b> MSK <i>p16</i>	<b>VL 1802</b> How I do it <i>p16</i>	<b>TA-HDT 6</b> Tumour ablation – Image guidance <i>p17</i>			
16:00						
15						
30						
45						
17:00	Break					
15						
30	<b>CF 1901</b> Response assessment and follow-up imaging <i>p17</i>	<b>FP 1902</b> Free Paper Session 2 <i>p17</i>	<b>BC 1903</b> Basic Course: Liver <i>p17</i>			
18:00						
15						
30						
45	Satellite Symposia					
19:00						





- CF:** Clinical Focus Session
- TF:** Technical Focus Session
- MTB:** Multidisciplinary Tumour Board
- VL:** Video Learning Session
- HL:** Honorary Lecture
- HDT:** Hands-on Device Training
- BC:** Basic Course
- FP:** Free Paper Session
- MM:** Morbidity and Mortality

## Monday, April 8

08:30-10:00

### Clinical Focus Session

#### CF 101 HCC – what you should know

-  101.1 HCC guidelines – what is new?  
*M. Varela (Oviedo/ES)*
-  101.2 Percutaneous ablation: best indication and which energy  
*A. Hocquelet (Lausanne/CH)*
-  101.3 Radioembolisation: who is a good candidate after the new classification  
*J. Ricke (Munich/DE)*
- 101.4 Scientific paper
- 101.5 Intermediate stage: what are the indications for combined IO therapies?  
*R. Lencioni (Pisa/IT)*
-  101.6 HCC and Immunotherapy  
*H.-J. Klumpen (Amsterdam/NL)*

10:30-12:00

### Clinical Focus Session

#### CF 201 Cancer immunology: basics

- 201.1 Immune alterations in solid tumours  
*W.H. Fridmann (Paris/FR)*
- 201.2 Immune checkpoint inhibitors – how do they work?  
*A. Digkila (Lausanne/CH)*
- 201.3 Immune response: the role of the tumour  
*G. Malouf (Strasbourg/FR)*
- 201.4 Immune response: the role of the microenvironment  
*C. Ottensmeier (Southampton/UK)*
- 201.5 Mechanisms of priming immune response using local treatment  
*M. Ahmed (Boston, MA/US)*



10:30-12:00

### Technical Focus Session

#### TF 202 Image guidance: case-based discussion

- 202.1 Ultrasound fusion guidance  
*L. Solbiati (Rozzano/IT)*
- 202.2 I have a CBCT and I do all the procedures  
*M.J.L. van Strijen (Nieuwegein/NL)*
- 202.3 I have an angio plus CT and I do all the procedures  
*F.G. Irani (Singapore/SG)*
- 202.4 MR guided interventions: where are we?  
*R.L. Cazzato (Strasbourg/FR)*
- 202.5 Robotic and stereotaxic assistance in IO  
*B.J. Wood (Bethesda, MD/US)*
- 202.6 Augmented reality  
*A. Gangi (Strasbourg/FR)*

10:30-12:00

**Hands-on Device Training****TA-HDT 1 Tumour ablation – Radiofrequency**Coordinators: *J. Abadal (Madrid/ES), F. Orsi (Milan/IT)*

12:15-14:30

**Satellite Symposia**

15:00-16:30

**Clinical Focus Session****CF 401 Hepatocarcinoma – practice in 2019**

- 401.1 Imaging of HCC: from EASL 2018 to LI-RADS  
*M. Ronot (Clichy/FR)*
- 401.2 TACE: new concepts  
*B. Guiu (Montpellier/FR)*
- 401.3 Is ablation only for non-surgical candidates?  
*L. Crocetti (Pisa/IT)*
- 401.4 Scientific paper
- 401.5 Ablation: how to select patients with best outcomes  
*A. Denys (Lausanne/CH)*
- 401.6 Radioembolisation: is dosimetry the key?  
*M.G.E.H. Lam (Utrecht/NL)*

15:00-16:30

**Clinical Focus Session****CF 402 Other organs**

- 402.1 Thyroid  
*R. Cervelli (Pisa/IT)*
- 402.2 Pancreas  
*G. Narayanan (Miami, FL/US)*
- 402.3 Adrenal  
*J. Garnon (Strasbourg/FR)*
- 402.4 Lymph nodes  
*G. Tzoumakidou (Lausanne/CH)*
- 402.5 Breast  
*J. Palussière (Bordeaux/FR)*







15:00-16:30

**TA-HDT 2** **Hands-on Device Training**  
**Tumour ablation – Radiofrequency**

Coordinators: *J. Abadal (Madrid/ES), F. Orsi (Milan/IT)*

17:00-18:30

**CF 501** **Clinical Focus Session**  
**Colorectal**

-  501.1 Prognostic factors in metastatic cancer (not TNM)  
*J.-E. Kurtz (Strasbourg/FR)*
-  501.2 Treatment strategies according to the ESMO guidelines  
*D. Arnold (Hamburg/DE)*
- 501.3 Immunotherapy in metastatic colorectal cancer: when and how  
*M. Fuchs (Munich/DE)*
- 501.4 Scientific paper
-  501.5 Local treatment in oligometastatic disease  
*M.R. Meijerink (Amsterdam/NL)*
-  501.6 Intra-arterial therapies in liver dominant disease  
*P.L. Pereira (Heilbronn/DE)*







17:00-18:30

**TF 502** **Technical Focus Session**  
**Tips and tricks: case-based discussion**

- 502.1 Painful bone metastases: HIFU or no HIFU?  
*A. Napoli (Rome/IT)*
- 502.2 Central lung tumours: how to manage?  
*A. Veltri (Orbassano/IT)*
- 502.3 How to treat sub-pleural lung disease?  
*F. Deschamps (Villejuif/FR)*
- 502.4 T1b renal cancer: how to achieve complete response?  
*D.J. Breen (Southampton/UK)*
- 502.5 Kidney ablation: difficult locations?  
*G.D. Schmit (Rochester, MN/US)*

17:00-19:00

**Basic Course****BC 503 Fundamentals in liver IO intervention**

-  503.1 Imaging and biopsy of liver tumours: what an IO should know  
*R. Duran (Lausanne/CH)*
-  503.2 Anatomy of liver arteries: tips and tricks for catheterism  
*J.K. Bell (Manchester/UK)*
-  503.3 Ablation tools for liver tumours: RFA, cryo and microwave, multipolar and monopolar  
*C. van der Leij (Maastricht/NL)*
-  503.4 Embolisation products: beads, lipiodol and others  
*L. Tselikas (Villejuif/FR)*

18:30-19:00

**Satellite Symposia**

e-voting



recommended for EBIR preparation



## Tuesday, April 9

07:45-08:15

### Satellite Symposia

08:30-10:00

#### Clinical Focus Session

##### CF 801 Intrahepatic cholangiocarcinoma



801.1 Peripheral intrahepatic cholangiocarcinoma vs Klatskin tumour: epidemiology, biology and treatment concepts  
*A. Vogel (Hannover/DE)*



801.2 Peripheral intrahepatic cholangiocarcinoma: the role of intra-arterial treatment  
*T.K. Helmberger (Munich/DE)*



801.3 Peripheral intrahepatic cholangiocarcinoma in cirrhotic patients: the role of interventional oncology  
*A. Hocquelet (Lausanne/CH)*

801.4 Surgical management of intrahepatic cholangiocarcinoma  
*T.M. van Gulik (Amsterdam/NL)*



801.5 How to prepare the liver for surgery  
*O.M. van Delden (Amsterdam/NL)*

Panel discussion

08:30-10:00

#### Clinical Focus Session

##### CF 802 Immunotherapy: actual clinical applications - what an IR should know

802.1 Main immunotherapeutic drugs in 2019 – efficacy and side effects  
*U. Martens (Heilbronn/DE)*

802.2 Immunotherapy in renal cell carcinoma – what's new in 2019?  
*A. Digkha (Lausanne/CH)*

802.3 Immunotherapy in lung cancer  
*C. Ottensmeier (Southampton/UK)*

802.4 Role of biopsies?  
*to be announced*

802.5 Imaging of immune response: state-of-the-art and challenges  
*C. Dromain (Lausanne/CH)*

10:30-11:30

##### HL 901 Honorary Lecture

*Laudation: T. de Baère (Villejuif/FR)*

901.1 Interventional Oncology: from Europe to South America  
*R.D. Garcia-Monaco (Buenos Aires/AR)*

10:30-12:00

#### Hands-on Device Training




##### TA-HDT 3 Tumour ablation – Microwave

*Coordinators: S. Ilyas (London/UK), P. Rao (Strasbourg/FR)*




11:30-12:00  
**FP 902 Free Paper Session 1**

12:15-14:30  
**Satellite Symposia**

15:00-16:30  
**CF 1101 Clinical Focus Session  
 Lung metastases**

-  1101.1 Rationale for local treatment  
*E.F. Smit (Amsterdam/NL)*
- 1101.2 SBRT: curative or delayed growth  
*to be announced*
- 1101.3 Surgery: utility and limitations  
*J. Jougon (Bordeaux/FR)*
- 1101.4 Scientific paper
-  1101.5 Management of oligometastatic patients: non-colorectal  
*J.-Y. Gaubert (Marseille/FR)*
-  1101.6 Management of oligometastatic patients: colorectal  
*A. Gillams (London/UK)*

15:00-16:30  
**CF 1102 Clinical Focus Session  
 Colorectal liver metastases**

-  1102.1 The oncologist's point of view: the ESMO tool box  
*G. Masi (Pisa/IT)*
-  1102.2 Radioembolisation: landmark clinical trials and patient selection  
*R. Sharma (London/UK)*
- 1102.3 Scientific paper
- 1102.4 Hepatic arterial infusion chemotherapy (HAIC): patient and drug selection  
*M. Ducreux (Villejuif/FR)*
-  1102.5 Ablation vs surgery for oligometastatic disease: evidence  
*C.T. Sofocleous (New York, NY/US)*
- 1102.6 TACE for colorectal mets: updated results  
*J. Golzarian (Minneapolis, MN/US)*

15:00-16:30  
**TA-HDT 4 Hands-on Device Training  
 Tumour ablation – Microwave**

*Coordinators: S. Ilyas (London/UK), P. Rao (Strasbourg/FR)*

17:00-18:30




**Clinical Focus Session****CF 1201 SBRT of liver and lung tumors: understanding mechanisms and limitations**

- 1201.1 Radiobiology: sensitive and resistant tumours  
*L.M. Kenny (Brisbane/AU)*
- 1201.2 SBRT for liver and lung tumours: the radiotherapist's perspective  
*M. Hawkins (Oxford/UK)*
- 1201.3 Response assessment: liver and lung  
*R.D. Suh (Los Angeles, CA/US)*
- 1201.4 SBRT of lung tumours: the limitations  
*to be announced*
- 1201.5 Ablation of lung tumours: the limitations  
*T. de Baère (Villejuif/FR)*

Panel discussion





17:00-18:30

**Clinical Focus Session****CF 1202 MSK: curative treatment**

-  1202.1 Essentials of biopsy in MSK tumours  
*A. Feydy (Paris/FR)*
- 1202.2 How to be curative in primary tumours: which IO treatment and where?  
*J.W. Jennings (St. Louis, MO/US)*
-  1202.3 How to avoid complications?  
*M.R. Callstrom (Rochester, MN/US)*
-  1202.4 Role of IO in oligometastatic bone disease  
*D. Filippiadis (Athens/GR)*
- 1202.5 Multimodality treatment for cure in bone tumours  
*R. Hoffmann (Dresden/DE)*

17:00-19:00

**Basic Course****BC 1203 Ablation and TACE of liver tumours**

-  1203.1 Ablation of primary liver tumours: good indications and methods  
*C. van der Leij (Maastricht/NL)*
-  1203.2 Ablation of metastatic liver tumours: when ablation should replace surgery  
*L. Tselikas (Villejuif/FR)*
-  1203.3 TACE of HCC: how to make it and how to manage the patient  
*R. Duran (Lausanne/CH)*
-  1203.4 TACE and ablation complications: how to recognise and manage them  
*J.K. Bell (Manchester/UK)*

18:30-19:00

**Satellite Symposia**

## Wednesday, April 10


07:45-08:15

### Satellite Symposia

08:30-10:00

#### Clinical Focus Session

##### CF 1501 Kidney cancer – current controversies

-  1501.1 Guidelines: from an IO perspective  
*D.A. Gervais (Boston, MA/US)*
- 1501.2 Understanding malignant potential with biopsy – histological viewpoint  
*S. Fleming (Dundee/UK)*
- 1501.3 Scientific paper
  - 1501.4 Ablation: which energy when?  
*G.D. Schmit (Rochester, MN/US)*
  - 1501.5 Ablation in the era of robotic partial nephrectomy: surgical perspective  
*A. Bex (Amsterdam/NL)*
  - 1501.6 Ablation in the era of robotic partial nephrectomy: IO perspective  
*D.J. Breen (Southampton/UK)*

08:30-10:00

#### Clinical Focus Session

##### CF 1502 Immunotherapy: where are we heading (research)

- 1502.1 HIT-IT (human intratumoral immunotherapy): ESMO recommendations  
*T. de Baère (Villejuif/FR)*
- 1502.2 Drugs for intratumoral injection  
*S. Champiat (Villejuif/FR)*
- 1502.3 Intratumoral viral injections: concepts and results  
*to be announced*
- 1502.4 Priming immune response with ablation  
*S.N. Goldberg (Jerusalem/IL)*
- 1502.5 Liquid biopsies  
*R.B. Corcoran (Boston, MA/US)*

10:30-12:00

#### Clinical Focus Session

##### CF 1601 Cancer pain management

- 1601.1 Systemic therapies for bone metastases  
*A. Antonuzzo (Pisa/IT)*
-  1601.2 IO and/or radiotherapy: when and where  
*S. Marcia (Cagliari/IT)*
- 1601.3 Nerve blocks and neurolysis  
*A.D. Kelekis (Athens/GR)*
-  1601.4 Bone metastases: thermal ablation with or without consolidation  
*U. Pua (Singapore/SG)*
- 1601.5 Embolisation in pain palliation in MSK tumours  
*R. Garcia Marcos (Valencia/ES)*
- 1601.6 Percutaneous consolidations: cement, screw...  
*R.-T. Hoffmann (Dresden/DE)*



e-voting



recommended for EBIR preparation



10:30-12:00

**Clinical Focus Session**  
**CF 1602 Emergency in oncology**



1602.1 Head and neck bleeding  
*A. Hakimé (Villejuif/FR)*



1602.2 Haemoptysis  
*R. Cioni (Pisa/IT)*



1602.3 How to manage ruptured HCC  
*J. Urbano (Madrid/ES)*



1602.4 Superior vena cava syndrome  
*W. Prevo (Amsterdam/NL)*



1602.5 Abdominal and pelvic bleeding  
*A.G. Ryan (Waterford City/IE)*

10:30-12:00

**Hands-on Device Training**  
**TA-HDT 5 Tumour ablation – Cryoablation and laser ablation**

*Coordinators: F.M. Gomez (Barcelona/ES), A.H. Mahnken (Marburg/DE)*

12:15-14:30

**Satellite Symposia**

15:00-16:30

**MTB 1801 Multidisciplinary Tumour Board**  
**MSK**

*Coordinators: M.R. Callstrom (Rochester, MN/US), S. Masala (Rome/IT)*

*Panellists: M. Borensztein (Buenos Aires/AR), J. Garnon (Strasbourg/FR), J.W. Jennings (St. Louis, MO/US), A.N. Kurup (Rochester, MN/US), P.J. Papagelopoulos (Athens/GR)*

Panel discussion

15:00-16:30

**VL 1802 Video Learning Session**  
**How I do it**

1802.1 Lung – difficult locations  
*F. Deschamps (Villejuif/FR)*

1802.2 Liver – guidance and targeting for ablation  
*G. Tzoumakidou (Lausanne/CH)*

1802.3 Liver – solving complex anatomical problems in TACE  
*I. Bargellini (Pisa/IT)*

1802.4 Liver – triple preparation technique for extended resection of Klatskin tumour  
*B. Guiu (Montpellier/FR)*

1802.5 Bone – pinning and stabilisation  
*X. Buy (Bordeaux/FR)*

1802.6 Kidney – T1b  
*T.D. Atwell (Rochester, MN/US)*








15:00-16:30

**TA-HDT 6 Hands-on Device Training**  
**Tumour ablation – Image guidance**

Coordinators: *A. Hakime (Villejuif/FR), L. Solbiati (Rozzano/IT)*

17:00-18:30

**CF 1901 Clinical Focus Session**  
**Response assessment and follow-up imaging**

-  1901.1 Ablation for MSK tumours  
*A. Feydy (Paris/FR)*
-  1901.2 TACE  
*Y. Arai (Tokyo/JP)*
-  1901.3 Radioembolisation  
*R. Salem (Chicago, IL/US)*
-  1901.4 Thermal ablation for lung cancer  
*R. Suh (Los Angeles, CA/US)*
-  1901.5 Thermal ablation for renal cancer  
*N. Patel (London/UK)*





Panel discussion

17:00-18:30

**FP 1902 Free Paper Session 2**

17:00-19:00

**BC 1903 Basic Course**  
**Radioembolisation**

-  1903.1 Currently available tools: resin glass, Yttrium, Holmium and others  
*R. Duran (Lausanne/CH)*
-  1903.2 Dosimetry for radiologists: understanding the dose  
*J.K. Bell (Manchester/UK)*
-  1903.3 Radioembolisation in HCC patients: good indications and good practice  
*C. van der Leij (Maastricht/NL)*
-  1903.4 Radioembolisation out of HCC: CRC, ICC, melanoma and others...  
*L. Tselikas (Villejuif/FR)*

18:30-19:00

**Satellite Symposia**

## Thursday, April 11

08:30-10:00

### Clinical Focus Session

#### CF 2101 New indications: localised prostate cancer

- 2101.1 Natural history of localised prostate cancer  
*R. Popert (London/UK)*
- 2101.2 Imaging gland disease  
*S.W.T.P. Heijmink (Amsterdam/NL)*
- 2101.3 Biopsy of prostate: when and how  
*R. Popert (London/UK)*
- 2101.4 Surgery or radiotherapy: which is the standard of care?  
*to be announced*
- 2101.5 IO options for localised disease  
*J. Fütterer (Nijmegen/NL)*

08:30-10:00

### Clinical Focus Session

#### CF 2102 Quality issues, research and patterns of practice in interventional oncology

- 2102.1 The role of IR in a centre of excellence in cancer care  
*C.T. Sofocleous (New York, NY/US)*
- 2102.2 Research in IO – the potential synergy with radiation oncology  
*N.I. Brown (Brisbane/AU)*
- 2102.3 An exemplar of collaboration in the treatment of lung cancer: heat, photons or both?  
*S.B. Solomon (New York, NY/US)*
- 2102.4 Quality Assurance – the key to front line status in oncology  
*L.M. Kenny (Brisbane/AU)*

Panel discussion



10:30-12:00

#### MM 2201 Morbidity & Mortality Conference

*Coordinators: M. Burrel (Barcelona/ES), J. Golzarian (Minneapolis, MN/US)*

## Hands-on Device Training Tumour ablation

Percutaneous ablation plays an increasingly fundamental role for the loco-regional treatment of cancer. Ablation technologies and equipment for live image guidance are developing quickly.

This Hands-on Device Training (HDT) aims to provide an overview of available technologies. Separate sessions will look at radiofrequency ablation, microwave ablation, cryoablation and laser ablation, as well as image guidance.

After a short kick-off presentation by the HDT coordinators, participants will have the opportunity to learn about the specifics, as well as the safe and effective use of the available technology in a hands-on setting.

Each HDT will feature a round-table discussion with the coordinators at the end of each session allowing participants to ask questions and give feedback.

### Monday, April 8

<b>TA-HDT 1 – Radiofrequency</b>	10:30-12:00
<b>TA-HDT 2 – Radiofrequency</b>	15:00-16:30

*Coordinators: J.M. Abadal (Madrid/ES), F. Orsi (Milan/IT)*

### Tuesday, April 9

<b>TA-HDT 3 – Microwave</b>	10:30-12:00
<b>TA-HDT 4 – Microwave</b>	15:00-16:30

*Coordinators: S. Ilyas (London/UK), P. Rao (Strasbourg/FR)*

### Wednesday, April 10

<b>TA-HDT 5 – Cryoablation and laser ablation</b>	10:30-12:00
---	-------------

*Coordinators: F.M. Gómez (Barcelona/ES),  
A.H. Mahnken (Marburg/DE)*

<b>TA-HDT 6 – Image guidance</b>	15:00-16:30
----------------------------------	-------------

*Coordinators: A. Hakimé (Villejuif/FR), L. Solbiati (Rozzano/IT)*

### How to participate

Please note that participation will be free of charge but places are limited to 25 people per session and will be allocated on a 'first come, first served' basis.

### Eligibility

As HDT sessions offer practical medical training, participation is for qualified medical professionals only.

## Safe sedation application during IR procedures

This practical workshop will give participants the opportunity to perform procedural sedation in a simulated environment and inform them on the most common respiratory problems during procedural sedation, as well as which instruments are available to make these interventions safer.

The simulation set-up consists of a full scale patient simulator with capnography, BIS Monitoring and TIVA/TCI pumps.

Participants will perform these therapies under the supervision of AQAI's experienced trainers.

### Learning objectives:

- To apply procedural sedation using different approaches
- To identify complications and challenges during procedural sedation
- To judge on the value of various monitoring technologies
- To recognise the additional value of capnography during sedation

A time schedule of the training sessions will be available soon.

### How to participate

Please note that participation will be free of charge but places are limited to 20 people per session and will be allocated on a 'first come, first served' basis.

### Eligibility

As these sessions offer practical medical training, participation is for qualified medical professionals only.

## Basic Course

### Liver

This format aims to offer a basic course series for beginners, focusing on a different organ each year. At ECIO 2019, the topic of this six-hour course will be Liver and will feature three distinct sessions, structured by the content included in the new European Curriculum and Syllabus for IR. It will allow a limited number of participants to receive a comprehensive overview of the topic, from diagnostics, imaging, treatment and follow-up. At the end of this interactive course, each participant will receive a confirmation of attendance.

#### How to participate

Please note that participation will be free of charge but places are limited to 40 people per session and will be allocated on a 'first come, first served' basis.

#### Monday, April 8

**BC 503 – Fundamentals in liver** 17:00-19:00

##### IO intervention

- 503.1 Imaging and biopsy of liver tumours: what an IO should know  
*R. Duran (Lausanne/CH)*
- 503.2 Anatomy of liver arteries: tips and tricks for catheterism  
*J.K. Bell (Manchester/UK)*
- 503.3 Ablation tools for liver tumours: RFA, cryo and microwave, multipolar and monopolar  
*C. van der Leij (Maastricht/NL)*
- 503.4 Embolisation products: beads, lipiodol and others  
*L. Tselikas (Villejuif/FR)*

#### Tuesday, April 9

**BC 1203 – Ablation and TACE** 17:00-19:00

##### of liver tumours

- 1203.1 Ablation of primary liver tumours: good indications and methods  
*C. van der Leij (Maastricht/NL)*
- 1203.2 Ablation of metastatic liver tumours: when ablation should replace surgery  
*L. Tselikas (Villejuif/FR)*
- 1203.3 TACE of HCC: how to make it and how to manage the patient  
*R. Duran (Lausanne/CH)*
- 1203.4 TACE and ablation complications: how to recognise and manage them  
*J.K. Bell (Manchester/UK)*

#### Wednesday, April 10

**BC 1903 – Radioembolisation** 17:00-19:00

- 1903.1 Currently available tools: resin glass, Yttrium, Holmium and others  
*R. Duran (Lausanne/CH)*
- 1903.2 Dosimetry for radiologists: understanding the dose  
*J.K. Bell (Manchester/UK)*
- 1903.3 Radioembolisation in HCC patients: good indications and good practice  
*C. van der Leij (Maastricht/NL)*
- 1903.4 Radioembolisation out of HCC: CRC, ICC, melanoma and others...  
*L. Tselikas (Villejuif/FR)*

## Registration

Online registration (secured payment) for ECIO 2019 is available at [www.ecio.org](http://www.ecio.org).

Please note that your registration must be submitted and full payment needs to be received by the respective registration deadlines. Otherwise the respective next higher fee will be due. Furthermore, please be advised that incomplete registrations (not containing full name, email and address) cannot be processed.

### Registration Fees

#### Early – until December 13, 2018 (23:59 CET)

Congress Registration	€ 610
CIRSE Member	€ 410
Resident / Nurse / Radiographer*	€ 270
Undergraduate Medical Student**	€ 0

#### Until February 21, 2019 (23:59 CET)

Congress Registration	€ 810
CIRSE Member	€ 570
Resident / Nurse / Radiographer*	€ 405
Undergraduate Medical Student**	€ 0

#### After February 21, 2019

Congress Registration	€ 880
CIRSE Member	€ 770
Resident / Nurse / Radiographer*	€ 440
Undergraduate Medical Student**	€ 0

\* To be accompanied by a certificate, signed by the head of department.

\*\* To be accompanied by a confirmation of student status at the time of congress, a one-page CV and a copy of a valid photo ID.

Registration fee inclusive 21% VAT in the Netherlands.

**Reduced CIRSE Member registration** is only available for members of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) in good standing.

### Method of payment

Registration fees are to be paid in Euros (€) by:  
Bank transfer or Credit Card (Visa or Mastercard)

### Cancellation of congress registration

CIRSE GmbH offers all pre-registered participants the possibility to take out cancellation insurance with its partner "Europäische Reiseversicherung". The insurance can only be booked during and until finalisation of the online registration process. The refund of the participant's registration fee due to cancellation of the registration or the change of registration

category is only possible with a valid insurance. All requests must be made to "Europäische Reiseversicherung" directly. Refunds will be given according to the terms and conditions of the "Europäische Reiseversicherung". CIRSE GmbH shall not be responsible for any refunds of registration fees.

Name changes will be handled as a cancellation and new registration.

### Additional information

All ECIO 2019 registrants will be able to print out an invoice of registration using their personal login details at [www.ecio.org](http://www.ecio.org).

Invoices will be issued by: CIRSE Congress Innovation Research GmbH, Neutorgasse 9/6, 1010 Vienna, Austria

## CME Credit Allowance

An application will be made to the EACCME® for CME accreditation of ECIO 2019.

## Important Addresses

### Congress Venue

RAI Convention Centre  
Europaplein 2-22  
1078 GZ Amsterdam, Netherlands

### Organising Secretariat

CIRSE Central Office  
Neutorgasse 9  
1010 Vienna, Austria  
Phone: +43 1 904 2003  
Fax: +43 1 904 2003 30  
Email: [info@cirse.org](mailto:info@cirse.org)  
Web: [www.ecio.org](http://www.ecio.org)

### Email Contacts

For general enquiries about the ECIO 2019 meeting, please send an email to [info@cirse.org](mailto:info@cirse.org).

In case of queries concerning registration for the ECIO 2019 meeting, please send an email to [registration@ecio.org](mailto:registration@ecio.org).

For information about the scientific programme of ECIO 2019, please send an email to [scientific@cirse.org](mailto:scientific@cirse.org).



## Accommodation

In cooperation with our travel partner Kuoni Congress, CIRSE has secured a great number of hotel rooms in Amsterdam for the benefit of our congress participants. For further information about the official ECIO hotels and room bookings, please refer to [www.ecio.org](http://www.ecio.org).

If you have any questions, please do not hesitate to contact:


### Kuoni Congress


Contact: Viera Bacova  
ecio2019@ch.kuoni.com  
+420 296 301 204

### List of hotels

Hotel name	Category	Single room (€)	Double room (€)	Travel time public transport	Travel time taxi
1 Pestana Amsterdam Riverside	5	278,81	299,81	20 min	9 min
2 Okura Amsterdam	5	288,00	317,50	8 min	5 min
3 Apollo Hotel Amsterdam	4	245,00	255,00	10 min	5 min
4 CitizenM Amsterdam City	4	218,93	232,88	12 min	7 min
5 Crowne Plaza South	4	262,19	262,19	15 min	8 min
6 Double Tree by Hilton	4	241,11	261,40	26 min	18 min
7 Element Amsterdam	4	232,14	242,74	20 min	6 min
8 Holiday Inn Amsterdam	4	230,45	245,40	walking distance	
9 Mercure Amsterdam City	4	187,86	210,36	23 min	6 min
10 NH Amsterdam Zuid	4	205,19	220,19	12 min	8 min
11 Novotel Amsterdam City	4	198,42	220,92	walking distance	
12 Motel One	3	134,24	164,59	walking distance	

*All room rates are in Euro (EUR) inclusive of breakfast, VAT and city tax based on 2018. Please note, that all taxes and service charges are subject to change according to the official legislation.*





The European Conference on Interventional Oncology is organised by CIRSE (Cardiovascular and Interventional Radiological Society of Europe).

The official congress website is: [www.ecio.org](http://www.ecio.org)

To contact the CIRSE Central Office or members of the committee please write to [info@cirse.org](mailto:info@cirse.org).

Cover: Bridge over Keizersgracht and Leidsegracht  
Amsterdam, Netherlands  
© [www.istockphoto.com](http://www.istockphoto.com)

GraphX by LOOP. ENTERPRISES media  
[www.loop-enterprises.com](http://www.loop-enterprises.com)

### ECIO 2019 Preliminary Programme

In case of any enquiries or comments,  
please contact us at [info@cirse.org](mailto:info@cirse.org)

© Cardiovascular and Interventional Radiological  
Society of Europe / 2018

*CIRSE does not accept responsibility for errors or misprints.*






# VECTORIO®

cTACE Mixing & Injection System

## Vectorio® efficacy & safety for improved cTACE mixing & delivery



UNBREAKABLE | USER-FRIENDLY | SHARP

Guerbet |   
Contrast for Life

**LIPIODOL® ULTRA-FLUID. Composition:** Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. **Indications (\*\*):** In diagnostic radiology - Hysterosalpingography - Ascending urethrography - Lymphography - Sialography - Fistulography and exploration of abscesses - Exploration of frontal sinuses - Pre and post-operative cholangiography. In interventional radiology - Visualisation and localization [by selective intra-arterial use during CT] of liver lesions in adults with known or suspected hepatocellular carcinoma - Visualisation, localisation and vascularisation during Trans-Arterial Chemo-Embolisation [TACE] of hepatocellular carcinoma at intermediate stage, in adults - Selective embolization in combination with Histoacryl glue [particularly for arteriovenous malformation or aneurysms] - Selective injections of LIPIODOL ULTRA-FLUID into the hepatic artery for diagnostic purposes where a spiral CT scan is not practical. In endocrinology - Prevention of severe cases of iodine deficiency. **Posology and method of administration (\*\*):** have to be adapted according to the type of examination, the territories explored, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to LIPIODOL ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrhage or bleeding - Hysterosalpingography during pregnancy or acute pelvic inflammation - Bronchography. In interventional radiology [Trans-Arterial Chemo-Embolization], Administration in liver areas with dilated bile ducts unless drainage has been performed. **Special warnings and special precautions for use (\*\*):** There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days from inadvertent systemic vascular injection or intravasation of LIPIODOL ULTRA-FLUID; Perform radiological monitoring during LIPIODOL ULTRA-FLUID injection and avoid use in patients with severely impaired lung function, cardiorespiratory failure or right-sided cardiac overload. Hypersensitivity: all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL ULTRA-FLUID. Thyroid: can cause hyperthyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and thyroid exploration should be performed before radiological examination. Chemo-Embolization: Trans-Arterial Chemo-Embolization is not recommended in patients with decompensated liver cirrhosis (Child-Pugh  $\geq 8$ ), advanced liver dysfunction, macroscopic invasion and/or extra-hepatic spread of the tumour. Renal insufficiency must be prevented by correct rehydration before and after the procedure. Oesophageal varices must be carefully monitored. Hepatic intra-arterial treatment can progressively cause an irreversible liver insufficiency in patients with serious liver malfunction and/or undergoing close multiple sessions. The risk of superinfection in the treated area is normally prevented by administration of antibiotics. Embolization with glue: An early polymerisation reaction may exceptionally occur between LIPIODOL ULTRA-FLUID and certain surgical glues, or even certain batches of glue. Before using new batches of LIPIODOL ULTRA-FLUID or surgical glue, the compatibility of LIPIODOL ULTRA-FLUID and the glue must be tested in vitro. **Interaction with other medicinal products and other forms of interaction (\*\*):** Mefloquin, Beta blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, Diuretics, Interleukin II. **Fertility, pregnancy and lactation (\*\*):** LIPIODOL ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL ULTRA-FLUID must be used. **Effects on ability to drive and use machines:** The effects on ability to drive and to use machines have not been investigated. **Undesirable effects (\*\*):** Most adverse effects are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhea, nausea, fever, pain, dyspnea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, cerebral embolism, retinal vein thrombosis, lymphoedema aggravation, hepatic vein thrombosis, granuloma. **Overdose (\*\*):** The total dose of LIPIODOL ULTRA-FLUID administered must not exceed 20 mL. **Pharmacodynamic properties (\*\*):** Pharmacotherapeutic group: X-ray contrast media, iodinated; ATC code: V08A D01. Water-insoluble iodinated contrast medium. **Presentation (\*\*):** 10 mL glass ampoule. **Marketing authorization holder (\*\*):** Guerbet - BP 57400 - F95943 Roissy CdG cedex - FRANCE. Information: tel: 33 (0) 1 45 91 50 00. **Revision:** April 24\*, 2018.

(\*) For complete information please refer to the local Summary of Product Characteristics (SPC).

(\*\*) Indications, volumes and presentations may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

VECTORIO® is a medical device of Class II (CE 0459) intended to be used by healthcare professionals only. Manufacturer: Medex, a Guerbet Group company. **Intended use: Lipiodol® Resistant Mixing & Injection System for conventional Trans-Arterial Chemo-Embolization (cTACE).**

For complete information please refer to country's local Package Information Leaflet & Vectorio® Instruction For Use (IFU).

Countries in which cTACE indication is registered: France, Japan, South Korea, Austria, Peru, Turkey, Hungary, Czech Republic, Mongolia, Argentina, The Netherlands, Vietnam, Mexico, Thailand, Taiwan, Brazil, Cambodia, Portugal, Ireland, Hong Kong, Philippines, Iran, New Zealand, Belgium & India.

For a copy of the SPC/IFU, please contact a member of Guerbet.